These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 12851868

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.
    Atzeni F, Ardizzone S, Sarzi-Puttini P, Colombo E, Maconi G, De Portu S, Carrabba M, Bianchi Porro G.
    Aliment Pharmacol Ther; 2005 Sep 01; 22(5):453-61. PubMed ID: 16128684
    [Abstract] [Full Text] [Related]

  • 3. Infliximab-induced lupus in Crohn's disease: a case report.
    Sarzi-Puttini P, Ardizzone S, Manzionna G, Atzeni F, Colombo E, Antivalle M, Carrabba M, Bianchi-Porro G.
    Dig Liver Dis; 2003 Nov 01; 35(11):814-7. PubMed ID: 14674674
    [Abstract] [Full Text] [Related]

  • 4. Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn's disease.
    Nancey S, Blanvillain E, Parmentier B, Flourié B, Bayet C, Bienvenu J, Fabien N.
    Inflamm Bowel Dis; 2005 Nov 01; 11(11):986-91. PubMed ID: 16239844
    [Abstract] [Full Text] [Related]

  • 5. Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNFalpha antibodies (infliximab).
    Garcia-Planella E, Domènech E, Esteve-Comas M, Bernal I, Cabré E, Boix J, Gassull MA.
    Eur J Gastroenterol Hepatol; 2003 Apr 01; 15(4):351-4. PubMed ID: 12655253
    [Abstract] [Full Text] [Related]

  • 6. Levels of anti-double-strained DNA but not antinuclear antibodies are associated with treatment efficacy and adverse outcomes in Crohn's disease patients treated with anti-TNFα.
    Kiss LS, Lovasz BD, Golovics PA, Vegh Z, Farkas K, Molnar T, Palatka K, Papp M, Mohas A, Szilagyi BK, Fekete SA, Mandel M, Lakatos PL.
    J Gastrointestin Liver Dis; 2013 Jun 01; 22(2):135-40. PubMed ID: 23799211
    [Abstract] [Full Text] [Related]

  • 7. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
    Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P.
    N Engl J Med; 2003 Feb 13; 348(7):601-8. PubMed ID: 12584368
    [Abstract] [Full Text] [Related]

  • 8. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study.
    Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N.
    Arthritis Res Ther; 2004 Feb 13; 6(6):R535-43. PubMed ID: 15535831
    [Abstract] [Full Text] [Related]

  • 9. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F.
    Arthritis Rheum; 2005 Jul 13; 52(7):2192-201. PubMed ID: 15986349
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Monoclonal antibody therapy for Crohn's disease.
    Selby W.
    Intern Med J; 2001 Mar 13; 31(2):73-4. PubMed ID: 11480481
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease.
    Sabate JM, Villarejo J, Lemann M, Bonnet J, Allez M, Modigliani R.
    Aliment Pharmacol Ther; 2002 Jun 13; 16(6):1117-24. PubMed ID: 12030953
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience.
    Cohen RD.
    Inflamm Bowel Dis; 2001 May 13; 7 Suppl 1():S17-22. PubMed ID: 11380038
    [Abstract] [Full Text] [Related]

  • 15. Maintenance infliximab therapy in patients with Crohn's disease: how long, how much, how frequent?
    Cuffari C, Lichtenstein GR.
    Gastroenterology; 2003 Jun 13; 124(7):1988-90. PubMed ID: 12806638
    [No Abstract] [Full Text] [Related]

  • 16. Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent.
    Subramanian S, Yajnik V, Sands BE, Cullen G, Korzenik JR.
    Inflamm Bowel Dis; 2011 Jan 13; 17(1):99-104. PubMed ID: 20629183
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity of infliximab in Crohn's disease.
    Hanauer SB.
    N Engl J Med; 2003 May 22; 348(21):2155-6; author reply 2155-6. PubMed ID: 12761378
    [No Abstract] [Full Text] [Related]

  • 18. [Treatment of inflammatory diseases: safety of long-term use of infliximab].
    Schaible TF.
    Presse Med; 2001 Mar 31; 30(12):610-3. PubMed ID: 11317923
    [Abstract] [Full Text] [Related]

  • 19. [Indications and results of infliximab in Crohn's disease].
    Karoui S, Boubaker J, Filali A.
    Tunis Med; 2004 Dec 31; 82(12):1057-63. PubMed ID: 15822505
    [Abstract] [Full Text] [Related]

  • 20. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.
    Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, Olson A, Bao W, Rutgeerts P.
    Clin Gastroenterol Hepatol; 2004 Jul 31; 2(7):542-53. PubMed ID: 15224278
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.